Carmustine, sold under the brand name BiCNU among others, is a nitrogen mustard beta chloro nitrosourea compound used as an alkylating agent in chemotherapy. It works by forming crosslinks between the two strands of a cancer cell's DNA, which blocks both DNA replication and transcription and prevents the cell from reproducing. It treats several brain cancers, including glioma, glioblastoma multiforme, medulloblastoma and astrocytoma, as well as multiple myeloma and both Hodgkin and non-Hodgkin lymphoma, and it is used to prepare patients for stem cell transplantation. A biodegradable wafer form called Gliadel delivers carmustine directly into the cavity left after brain tumor surgery, releasing the drug locally without needing to cross the blood brain barrier.
Facts
Classification
Approval Status ATC ClassSourced to the subject's own accountL: Antineoplastic and Immunomodulating Agents 2 Route of AdministrationSourced to the subject's own account First Approved / Isolated Year Connections
Sources
1. Carmustine (Wikipedia)
2. Anatomical Therapeutic Chemical Classification System (Wikipedia)
WikipediaFirst-level anatomical group codes, Code L
Antineoplastic and immunomodulating agents
- Route of administration
View the Source 3. FDA: BiCNU (carmustine) Label
Approval historyQuote, Approval history
Carmustine (BiCNU) received FDA approval in 1977
View the Source Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.